keyword
MENU ▼
Read by QxMD icon Read
search

Secukinumab

keyword
https://www.readbyqxmd.com/read/28087133/secukinumab-sustains-early-patient-reported-outcome-benefits-through-1%C3%A2-year-results-from-2-phase-iii-randomized-placebo-controlled-clinical-trials-comparing-secukinumab-with-etanercept
#1
Bruce Strober, Alice B Gottlieb, Bintu Sherif, Patrick Mollon, Isabelle Gilloteau, Lori McLeod, Todd Fox, Margaret Mordin, Ari Gnanasakthy, Charis Papavassilis, Mark G Lebwohl
BACKGROUND: Psoriasis is a chronic condition with negative impact on patients' quality of life that most often requires lifelong effective and safe treatment. OBJECTIVE: This analysis focused on the effect of secukinumab treatment on patient-reported health-related quality of life as assessed by the Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis. METHODS: The proportion of subjects achieving DLQI score 0/1 response at week 24, time to DLQI score 0/1 response, and sustained DLQI score 0/1 response up to week 52 were compared between secukinumab and etanercept...
January 10, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28042732/the-potential-utility-of-tildrakizumab-an-interleukin-23-inhibitor-for-the-treatment-of-psoriasis
#2
Zenas Z N Yiu, Richard B Warren
The approved biologic therapies are effective for the treatment of psoriasis, but have limitations. Tildrakizumab has a different mechanism of action and is a humanized immunoglobulin G1κ that binds to the p19 subunit of IL23. Areas covered: Phase I, II and III clinical trials investigated the pharmacokinetics, efficacy, safety and immunogenicity of tildrakizumab for patients with psoriasis. The mean half-life of tildrakizumab is between 20.2 to 28.2 days. Tildrakizumab achieved a PASI 75 of 66% and 74% at week 16 for the doses of 100 mg and 200 mg respectively in a phase IIb randomised clinical trial (RCT), and PASI 75 of 61%/64% and 62%/66% at week 12 for 100 mg and 200 mg respectively in two phase III RCTs...
January 1, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28042711/the-impact-of-pasi-75-and-pasi-90-on-quality-of-life-in-moderate-to-severe-psoriasis-patients
#3
Michael Abrouk, M Nakamura, T H Zhu, B Farahnik, J Koo, T Bhutani
BACKGROUND: It is well known that psoriasis significantly impacts patients' quality of life (QoL). With the introduction of improved treatment modalities with biologic agents, more patients with moderate to severe psoriasis are able to achieve better results as measured by the Psoriasis Area and Severity Index (PASI). PASI 75 indicates a 75% or greater reduction in PASI scores from baseline and is indicative of excellent disease improvement. With newer biologic agents such as secukinumab, ixekizumab and brodalumab, patients are now capable of achieving PASI 90, introducing additional clinical decisions for physicians when considering treatment options...
December 31, 2016: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28026823/anti%C3%A2-cytokine-therapy-for-psoriasis-not-only-tnf%C3%A2-%C3%AE-blockers-overview-of-reports-on-the-effectiveness-of-therapy-with-il%C3%A2-12-il%C3%A2-23-and-t-and-b-lymphocyte-inhibitors
#4
Dominika Wcisło-Dziadecka, Martyna Zbiciak, Ligia Brzezińska-Wcisło, Urszula Mazurek
TNF‑α inhibitors - infliximab, etanercept and adalimumab - can be used in the treatment of psoriasis vulgaris and psoriatic arthritis, along with other inhibitors of proinflammatory cytokines, such as interleukin‑12 (IL‑12) and IL‑23. This paper presents the results of research on the use of biological drugs other than the tumor necrosis factor blockers (TNF‑α), namely inhibitors of IL‑12 and IL‑23 (ustekinumab), T‑cell inhibitors (alefacept and efalizumab), B‑cell inhibitors (rituximab), anti‑IL‑17 agents (secukinumab, ixekizumab, and brodalumab) and IL23p19 inhibitors (guselkumab and tildrakizumab)...
December 8, 2016: Postȩpy Higieny i Medycyny Doświadczalnej
https://www.readbyqxmd.com/read/27990383/biologics-use-in-indian-psoriasis-patients
#5
Murlidhar Rajagopalan, Asit Mital
The biologics currently in use for psoriasis in India are etanercept, infliximab and recently introduced itolizumab and secukinumab. Biosimilars, expected to play a significant role in psoriasis management in future, have also been available for the last few years. Patients with psoriasis may be considered eligible to receive treatment with any of the licensed biologic interventions when they fulfill the eligibility criteria. The decision to proceed with treatment must be made in collaboration with the patient and include a careful assessment of the associated risks and benefits...
November 2016: Indian Dermatology Online Journal
https://www.readbyqxmd.com/read/27984714/il-17-blockade-in-psoriasis
#6
Patrick R Burkett, Vijay K Kuchroo
IL-17A both directly induces and synergizes with other cytokines to promote autoimmune tissue inflammation. Secukinumab and ixekizumab are monoclonal antibodies (mAb) that inhibit interleukin-17A. These two agents were recently approved for treatment of psoriasis, and secukinumab is also approved for treatment of two spondyloarthropathies, psoriatic arthritis and ankylosing spondylitis.
December 15, 2016: Cell
https://www.readbyqxmd.com/read/27981221/successful-use-of-secukinumab-in-pustular-psoriasis
#7
Jensen Yeung, Venus Valbuena
No abstract text is available yet for this article.
November 2016: JAAD Case Reports
https://www.readbyqxmd.com/read/27981219/successful-treatment-of-type-ii-pityriasis-rubra-pilaris-with-secukinumab
#8
Marie-Léa Gauci, Marie Jachiet, Jeremy Gottlieb, Isabelle Madeleine-Chambrin, Michel Rybojad, Martine Bagot, Jean-David Bouaziz
No abstract text is available yet for this article.
November 2016: JAAD Case Reports
https://www.readbyqxmd.com/read/27971733/cost-effectiveness-analysis-of-secukinumab-compared-to-current-biologics-sequences-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-in-france
#9
E Duteil, C Cariou, A Schmidt, K Benjamin, J Duco
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971629/cost-per-responder-of-apremilast-versus-infliximab-biosimilar-etanercept-adalimumab-ustekinumab-and-secukinumab-in-patients-with-moderate-to-severe-psoriasis-in-spain
#10
J M Martinez-Sesmero, C Schoendorff, T Caloto
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971628/cost-effectiveness-of-secukinumab-compared-with-ustekinumab-and-etanercept-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-in-greece
#11
C Tzanetakos, G Kourlaba, M Chatzikou, C Antoniou, D Ioannidis, Lefaki, A Petridis, D Rigopoulos, A Roussaki-Schulze, D Sotiriadis, N Maniadakis
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971624/cost-effectiveness-of-secukinumab-as-first-biologic-treatment-for-psoriasis-compared-with-initiating-other-biologic-therapy-in-germany
#12
M Augustin, T Krieger, D McBride, C N Graham, N Melzer, J Kneidl, K Neidhardt
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971619/cost-effectiveness-analysis-of-ixekizumab-vs-secukinumab-in-sequential-biologic-treatment-of-psoriasis-in-the-uk
#13
E Johansson, A Svedbom, G Kumar, S Hartz, S Kiri
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971463/assessing-the-cost-effectiveness-of-secukinumab-compared-to-tnf-inhibitors-as-second-line-biologic-treatment-in-psoriatic-arthritis
#14
A Lang, M Costa-Scharplatz, A Fasth, P Gunda, S M Jugl, L Jacobsson
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971456/a-cost-per-responder-analysis-of-secukinumab-vs-adalimumab-based-on-a-matching-adjusted-indirect-comparison-for-the-treatment-of-ankylosing-spondylitis-from-a-german-payer-perspective
#15
P Gunda, A Kandhare, E Nikoglou, S M Jugl, J Kneidl, K Neidhardt
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971446/budget-impact-of-secukinumab-for-ankylosing-spondylitis-in-the-uk
#16
A Halliday, V Hacking, S M Jugl, P Gunda, E Nikoglou, L Miles, C N Graham
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971443/budget-impact-model-of-secukinumab-in-the-treatment-of-ankylosing-spondylitis-as-and-with-psoriatic-arthritis-psa-in-italy
#17
G L Colombo, S Di Matteo, G M Bruno, M C Valentino, M Oselin, A Roccia
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971439/secukinumab-in-the-management-of-psoriatic-arthritis-in-greece-a-budget-impact-analysis
#18
M Geitona, H Kousoulakou, M Chatzikou, K Doukoumetzidis, D Patrikos
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971434/a-budget-impact-analysis-of-secukinumab-in-the-management-of-ankylosing-spondylitis-in-greece
#19
H Kousoulakou, M Geitona, M Chatzikou, K Doukoumetzidis, D Patrikos
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27971028/budget-impact-analysis-of-secukinumab-in-moderate-to-severe-plaque-psoriaris-ankylosing-spondylitis-and-psoriatic-arthritis-in-france
#20
E Duteil, L Rachdi, C Cariou, K Benjamin, G Leiba, J Duco
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
keyword
keyword
30575
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"